Abbott Labs (ABT) Stock Jumps 4% After Earnings Beat and Raised Outlook

TLDR

• ABT rose nearly 4% premarket after beating Q2 earnings and revenue estimates
• Adjusted EPS came in at $1.31, above the $1.28 analyst estimate
• Total Q2 revenue rose 13% to $12.59 billion, driven by a 42% jump in diagnostics sales
• Full-year adjusted EPS guidance raised to $5.45–$5.60, up from $5.38–$5.58
• Diagnostics beat was the first in six quarters, boosted by the Exact Sciences acquisition

---

Abbott Laboratories beat Wall Street estimates for the second quarter and raised its full-year profit outlook, sending ABT stock up nearly 4% in premarket trading on Thursday.

Abbott Laboratories, ABT

Adjusted EPS came in at $1.31, topping the $1.28 analyst estimate. Total revenue rose 13% year-over-year to $12.59 billion, edging past the $12.52 billion consensus forecast.

The big story this quarter was diagnostics. Sales in that segment jumped 42% to $3.09 billion, beating estimates of $3.02 billion — and marking the first diagnostics beat in six quarters.

ABBOTT $ABT Q2’26 EARNINGS HIGHLIGHTS

🔹 Revenue: $12.59B (Est. $12.48B) 🟢; +13.0% YoY
🔹 Adj. EPS: $1.31 (Est. $1.28) 🟢; +4.0% YoY
🔹 Diagnostics Rev: $3.09B; +42.3% YoY

FY26 Guide:
🔹 Adj. EPS: $5.45-$5.60; raised from $5.38-$5.58 🟢
🔹 Comparable Sales Growth: 6.5% to… pic.twitter.com/DqowIO0TCr

— Wall St Engine (@wallstengine) July 16, 2026

Much of that gain came from the recently acquired Exact Sciences assets, including the colorectal cancer screening test Cologuard and breast cancer assay Oncotype DX. Cologuard posted mid-teens growth, helped by an expanding base of both new and returning users.

The diagnostics results are helping Abbott offset a continuing drop in COVID-19 testing revenue, which had been a meaningful contributor in prior years.

Medical Devices Hold Firm

Medical device sales grew 9% to $5.85 billion, just ahead of the $5.82 billion estimate. Abbott’s electrophysiology and structural heart segments are seen as more resilient than peers facing pressure from lower surgical volumes and rising uninsured rates.

Diabetes Care, which includes the FreeStyle Libre and Lingo CGM products, posted a 10.5% sales rise to $2.19 billion. J.P. Morgan analyst Robbie Marcus noted that the global CGM market appears to have settled into an 8%–12% growth range, with Abbott likely sitting in the 8%–10% band going forward.

Nutrition was the weak spot — that segment saw revenue fall 3.1% due to lower volumes and recent pricing actions.

Outlook Lifted

Abbott raised its full-year adjusted EPS guidance to $5.45–$5.60, up from the prior range of $5.38–$5.58. The company reaffirmed its comparable sales growth guidance of 6.5%–7.5%.

For Q3, Abbott guided adjusted EPS of $1.38–$1.46, compared to the analyst estimate of $1.42 — putting the midpoint roughly in line with expectations.

On a GAAP basis, net profit fell to $928 million, or $0.53 per share, from $1.78 billion, or $1.01 per share, a year ago, reflecting costs tied to acquisitions and other one-time items.

Established pharmaceuticals sales rose more than 8%, adding to the overall revenue beat.

The diagnostics beat — the first in six quarters — came directly from the Exact Sciences acquisition closing, giving Abbott a new growth engine at a time when its legacy testing business continues to shrink.